On the public citation graph
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
0 signed · 569 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2019.12843openalex-snapshot
Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction
inferredcites →https://doi.org/10.1001/jama.2019.17576openalex-snapshot
Neglecting Major Health Problems and Broadcasting Minor, Uncertain Issues in Lifestyle Science
inferredcites →https://doi.org/10.1001/jama.2020.1906openalex-snapshot
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
inferredcites →https://doi.org/10.1001/jamacardio.2017.3983openalex-snapshot
Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction
inferredcites →https://doi.org/10.1002/ehf2.12850openalex-snapshot
Effects of Dapagliflozin on Congestion Assessed by Remote Pulmonary Artery Pressure Monitoring
inferredcites →https://doi.org/10.1002/ejhf.1299openalex-snapshot
Relationship Between Changing Patient-Reported Outcomes and Subsequent Clinical Events in Patients with Chronic Heart Failure: Insights From HF-ACTION
inferredcites →https://doi.org/10.1002/ejhf.1473openalex-snapshot
Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin Improves Cardiac Function in Non-Diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction
inferredcites →https://doi.org/10.1002/ejhf.156openalex-snapshot
Cardiopulmonary Exercise Testing in Systolic Heart Failure in 2014: The Evolving Prognostic Role
inferredcites →https://doi.org/10.1007/s00125-017-4509-7openalex-snapshot
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
inferredcites →https://doi.org/10.1007/s10557-018-06850-0openalex-snapshot
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?
inferredcites →https://doi.org/10.1007/s10557-018-6786-xopenalex-snapshot
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
inferredcites →https://doi.org/10.1016/j.ahj.2004.12.010openalex-snapshot
Monitoring clinical changes in patients with heart failure: A comparison of methods
inferredcites →https://doi.org/10.1016/j.ehj.2004.02.030openalex-snapshot
Early identification of left ventricular remodelling after myocardial infarction, assessed by transthoracic 3D echocardiography
inferredcites →https://doi.org/10.1016/j.jacbts.2020.02.004openalex-snapshot
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
inferredcites →https://doi.org/10.1016/j.jacc.2010.05.011openalex-snapshot
Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction
inferredcites →https://doi.org/10.1016/j.jacc.2017.08.012openalex-snapshot
Cardiopulmonary Exercise Testing
inferredcites →https://doi.org/10.1016/j.jacc.2019.01.056openalex-snapshot
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
inferredcites →https://doi.org/10.1016/j.jacc.2019.01.072openalex-snapshot
Exercise Intolerance in Patients With Heart Failure
inferredcites →https://doi.org/10.1016/j.jacc.2019.11.031openalex-snapshot
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
inferredcites →https://doi.org/10.1016/j.jchf.2016.03.022openalex-snapshot
Cardiopulmonary Exercise Testing in Heart Failure
inferredcites →https://doi.org/10.1016/j.jcmg.2008.05.012openalex-snapshot
Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction
inferredcites →https://doi.org/10.1016/j.jcmg.2010.10.008openalex-snapshot
Left Ventricular Remodeling in Heart Failure
inferredcites →https://doi.org/10.1016/j.jcmg.2020.07.042openalex-snapshot
Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure
inferredcites →https://doi.org/10.1016/s0735-1097(00)00531-3openalex-snapshot
Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure
inferredcites →https://doi.org/10.1016/s0735-1097(00)00691-4openalex-snapshot
Oxygen uptake efficiency slope: an index of exercise performance and cardiopulmonary reserve requiring only submaximal exercise
inferredcites →https://doi.org/10.1016/s0735-1097(99)00630-0openalex-snapshot
Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling
inferredcites →https://doi.org/10.1056/nejmoa1504720openalex-snapshot
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1611925openalex-snapshot
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1812389openalex-snapshot
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1911303openalex-snapshot
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
inferredcites →https://doi.org/10.1056/nejmoa2022190openalex-snapshot
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
inferredcites →https://doi.org/10.1111/dom.12572openalex-snapshot
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
inferredcites →https://doi.org/10.1161/01.cir.76.1.44openalex-snapshot
Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.
inferredcites →https://doi.org/10.1161/01.cir.96.1.116openalex-snapshot
End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators
inferredcites →https://doi.org/10.1161/cir.0000000000000659openalex-snapshot
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
inferredcites →https://doi.org/10.1161/circulationaha.115.012427openalex-snapshot
Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion
inferredcites →https://doi.org/10.1161/circulationaha.118.036459openalex-snapshot
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
inferredcites →https://doi.org/10.1161/circulationaha.119.042375openalex-snapshot
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
inferredcites →https://doi.org/10.1161/circulationaha.119.042929openalex-snapshot
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction
inferredcites →https://doi.org/10.1164/ajrccm.166.1.at1102openalex-snapshot
ATS Statement: Guidelines for the Six-Minute Walk Test
inferredcites →https://doi.org/10.18632/aging.102175openalex-snapshot
The anti-inflammatory effects of SGLT inhibitors
inferredcites →https://doi.org/10.2337/dc17-1096openalex-snapshot
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
inferredcites →https://doi.org/10.2337/dc19-2187openalex-snapshot
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
inferredcites →https://doi.org/10.3109/10976640009148691openalex-snapshot
Reduction in Sample Size for Studies of Remodeling in Heart Failure by the Use of Cardiovascular Magnetic Resonance
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4688427openalex-extracted
Effects of Sglt2 Inhibitors on Cardiac Mechanics in Hispanic and Black Diabetic Patients Without Cardiovascular Diseases
inferred← citeshttps://doi.org/10.1001/jamacardio.2021.0379openalex-snapshot
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.5135openalex-snapshot
SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure
inferred← citeshttps://doi.org/10.1002/bmc.5755openalex-snapshot
A sensitive ultra‐performance liquid chromatography‐tandem mass spectrometry method for the simultaneous quantification of assay and trace‐level genotoxic tosylate analogs (methyl and ethyl) in empagliflozin and its tablet dosage forms
inferred← citeshttps://doi.org/10.1002/clc.23603openalex-snapshot
Should SGLT2i be used prior to transcatheter edge‐to‐edge repair for secondary mitral regurgitation?
inferred← citeshttps://doi.org/10.1002/clc.23849openalex-snapshot
Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction
inferred← citeshttps://doi.org/10.1002/clc.24228openalex-snapshot
Impact of anemia on clinical outcomes in patients with acute heart failure: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/clc.70192openalex-snapshot
Impact of Empagliflozin Versus Dapagliflozin on Left Ventricular Remodeling in Heart Failure Patients: A 1‐Year Comparative Study
inferred← citeshttps://doi.org/10.1002/edm2.514openalex-snapshot
Efficacy of Sodium‐Glucose Cotransporter‐2 Inhibitors in Patients With Acute Myocardial Infarction: A Meta‐Analysis of Randomised Controlled Trials
inferred← citeshttps://doi.org/10.1002/ehf2.13148openalex-snapshot
Early Initiation of SGLT2 Inhibitors is Important, Irrespective of Ejection Fraction: SOLOIST-WHF in Perspective
inferred← citeshttps://doi.org/10.1002/ehf2.13374openalex-snapshot
Time to Cardiovascular Benefits of Empagliflozin: A Post Hoc Observation from the EMPA-REG OUTCOME Trial
inferred← citeshttps://doi.org/10.1002/ehf2.13406openalex-snapshot
Design and Rationale of the EMPA-VISION Trial: Investigating the Metabolic Effects of Empagliflozin in Patients with Heart Failure
inferred← citeshttps://doi.org/10.1002/ehf2.13483openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibitor Effects on Heart Failure Hospitalization and Cardiac Function: Systematic Review
inferred← citeshttps://doi.org/10.1002/ehf2.13645openalex-snapshot
SGLT2 Inhibitors and Cardiac Remodelling: A Systematic Review and Meta-Analysis of Randomized Cardiac Magnetic Resonance Imaging Trials
inferred← citeshttps://doi.org/10.1002/ehf2.13822openalex-snapshot
Can Glucose-Lowering Medications Improve Outcomes in Non-Diabetic Heart Failure Patients? A Bayesian Network Meta-Analysis
inferred← citeshttps://doi.org/10.1002/ehf2.14005openalex-snapshot
Promise of Sodium–Glucose Co-Transporter-2 Inhibitors in Heart Failure with Mildly Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1002/ehf2.14331openalex-snapshot
Rationale and Design of the Biventricular Evaluation of Gliflozins Effects In chroNic Heart Failure: BEGIN-HF Study
inferred← citeshttps://doi.org/10.1002/ehf2.14555openalex-snapshot
Cardiac Reverse Remodelling by Imaging Parameters with Recent Changes to Guideline Medical Therapy in Heart Failure
inferred← citeshttps://doi.org/10.1002/ehf2.14784openalex-snapshot
The Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Outcomes After Cardiac Resynchronization Therapy
inferred← citeshttps://doi.org/10.1002/ehf2.14830openalex-snapshot
Empagliflozin to Prevent Progressive Adverse Remodelling After Myocardial Infarction (EMPRESS-MI): Rationale and Design
inferred← citeshttps://doi.org/10.1002/ehf2.14993openalex-snapshot
Impact of SGLT2 Inhibition on Markers of Reverse Cardiac Remodelling in Heart Failure: Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/ehf2.15095openalex-snapshot
Cardiac Remodelling in the Era of the Recommended Four Pillars Heart Failure Medical Therapy
inferred← citeshttps://doi.org/10.1002/ehf2.15296openalex-snapshot
Dapagliflozin Effect On Functional Mitral Regurgitation and Myocardial Remodelling: The DEFORM Trial
inferred← citeshttps://doi.org/10.1002/ehf2.15408openalex-snapshot
SGLT2 Inhibitors for the Prevention and Treatment of Heart Failure: A Scientific Statement of the HFA and the HFAI
inferred← citeshttps://doi.org/10.1002/ejhf.2249openalex-snapshot
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
inferred← citeshttps://doi.org/10.1002/ejhf.2381openalex-snapshot
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
inferred← citeshttps://doi.org/10.1002/ejhf.2560openalex-snapshot
Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction ( DAPA‐VO 2 ): a randomized clinical trial
inferred← citeshttps://doi.org/10.1002/ejhf.2753openalex-snapshot
Weighing in on Weight Loss in Heart Failure with Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1002/ejhf.2883openalex-snapshot
Cardiac Reverse Remodelling with Vericiguat: Victory or no Victory?
inferred← citeshttps://doi.org/10.1002/ejhf.2884openalex-snapshot
Impact of Dapagliflozin on Cardiac Remodelling in Patients with Chronic Heart Failure: The DAPA-MODA Study
inferred← citeshttps://doi.org/10.1002/ejhf.3101openalex-snapshot
Effects of Empagliflozin on Collagen Biomarkers in Patients with Heart Failure: Findings from the EMPEROR Trials
inferred← citeshttps://doi.org/10.1002/ejhf.3129openalex-snapshot
The Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Left Cardiac Remodelling in Heart Failure with Reduced Ejection Fraction: Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/ejhf.3219openalex-snapshot
Sodium–Glucose Cotransporter 2 Inhibitors and Skeletal Muscle
inferred← citeshttps://doi.org/10.1002/ejhf.3391openalex-snapshot
Changes in 6‐min walk test is an independent predictor of death in chronic heart failure with reduced ejection fraction
inferred← citeshttps://doi.org/10.1002/ejhf.3560openalex-snapshot
Empagliflozin to Prevent Worsening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI)
inferred← citeshttps://doi.org/10.1002/ejhf.3633openalex-snapshot
Myocardial Ketone Body Oxidation Contributes to Empagliflozin-Induced Improvements in Cardiac Contractility in Murine Heart Failure
inferred← citeshttps://doi.org/10.1002/jcp.31264openalex-snapshot
Empagliflozin, a sodium‐glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome
inferred← citeshttps://doi.org/10.1002/jcph.1987openalex-snapshot
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis
inferred← citeshttps://doi.org/10.1002/jhm.12798openalex-snapshot
Clinical progress note: Indications for and management of sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors in hospitalized patients
inferred← citeshttps://doi.org/10.1002/phar.2527openalex-snapshot
Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction
inferred← citeshttps://doi.org/10.1007/164_2026_827openalex-snapshot
Clinical Evidence of Cardioprotective Effects of SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-031-39315-0_22openalex-snapshot
Reversibility of Cardiac Remodeling in Hypertensive Patients with Heart Failure
inferred← citeshttps://doi.org/10.1007/s00228-023-03495-3openalex-snapshot
Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis
inferred← citeshttps://doi.org/10.1007/s00228-024-03660-2openalex-snapshot
Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients
inferred← citeshttps://doi.org/10.1007/s00228-024-03731-4openalex-snapshot
Letter to the editor: "Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials involving 2624 patients"
inferred← citeshttps://doi.org/10.1007/s00228-024-03733-2openalex-snapshot
Author’s reply to the letter to the editor: “Effects of dapagliflozin and empagliflozin on 6‑min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta‑analysis of randomized controlled trials involving 2624 patients”
inferred← citeshttps://doi.org/10.1007/s00392-021-01913-zopenalex-snapshot
Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis
inferred← citeshttps://doi.org/10.1007/s00392-021-01954-4openalex-snapshot
SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure—further evidence for improved hemodynamics by continuous pressure monitoring
inferred← citeshttps://doi.org/10.1007/s00392-023-02164-wopenalex-snapshot
Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial
inferred← citeshttps://doi.org/10.1007/s00392-026-02886-7openalex-snapshot
Impact of SGLT2 inhibitors in patients with Fabry disease
inferred← citeshttps://doi.org/10.1007/s00398-022-00521-xopenalex-snapshot
Gemeinsamer Kommentar der Deutschen Gesellschaft für Kardiologie (DGK) und der Deutschen Gesellschaft für Thorax‑, Herz- und Gefäßchirurgie (DGTHG) zu den Leitlinien (2021) der ESC/EACTS zum Management von Herzklappenerkrankungen
inferred← citeshttps://doi.org/10.1007/s00592-022-02018-3openalex-snapshot
Diabetes medication following heart transplantation: a focus on novel cardioprotective therapies—a joint review from endocrinologists and cardiologists
inferred← citeshttps://doi.org/10.1007/s10554-021-02443-5openalex-snapshot
Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial
inferred← citeshttps://doi.org/10.1007/s10557-021-07311-xopenalex-snapshot
Empagliflozin Ameliorates Ouabain-Induced Na+ and Ca2+ Dysregulations in Ventricular Myocytes in an Na+-Dependent Manner
inferred← citeshttps://doi.org/10.1007/s10557-022-07371-7openalex-snapshot
SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction
inferred← citeshttps://doi.org/10.1007/s10557-023-07469-6openalex-snapshot
Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes
inferred← citeshttps://doi.org/10.1007/s10557-024-07604-xopenalex-snapshot
Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?
inferred← citeshttps://doi.org/10.1007/s10557-026-07904-4openalex-snapshot
Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study
inferred← citeshttps://doi.org/10.1007/s10741-022-10256-4openalex-snapshot
Effects of SGLT2 inhibitors on cardiac structure and function
inferred← citeshttps://doi.org/10.1007/s10741-022-10281-3openalex-snapshot
Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s10741-023-10324-3openalex-snapshot
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews
inferred← citeshttps://doi.org/10.1007/s10741-023-10340-3openalex-snapshot
Patient phenotype profiling using echocardiography and natriuretic peptides to personalise heart failure therapy
inferred← citeshttps://doi.org/10.1007/s10741-024-10467-xopenalex-snapshot
Could SGLT2 inhibitors improve outcomes in patients with heart failure and significant valvular heart disease? Need for action
inferred← citeshttps://doi.org/10.1007/s10741-026-10607-5openalex-snapshot
Dapagliflozin effect on pericardial fat deposition: lessons from the DAPA EAT
inferred← citeshttps://doi.org/10.1007/s10840-025-02014-xopenalex-snapshot
Impact of SGLT2 inhibitor on clinical and echocardiographic outcomes in patients with CRT during long-term period
inferred← citeshttps://doi.org/10.1007/s10840-025-02190-wopenalex-snapshot
Cardioprotective effects of Sodium-Glucose cotransporter-2 inhibitors in patients undergoing ventricular tachycardia (VT) ablation: a propensity-matched cohort study
inferred← citeshttps://doi.org/10.1007/s11096-022-01504-6openalex-snapshot
The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s11096-025-01908-0openalex-snapshot
Effects of SGLT2 inhibitors on health-related quality of life and functional capacity in patients with heart failure with and without diabetes: a meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s11255-025-04965-6openalex-snapshot
SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients
inferred← citeshttps://doi.org/10.1007/s11845-024-03744-zopenalex-snapshot
The effect of Empagliflozin on echocardiographic parameters in diabetic patients after acute myocardial infarction: A systematic review and meta-analysis with trial sequential analysis
inferred← citeshttps://doi.org/10.1007/s11886-021-01511-5openalex-snapshot
Patient-Reported Outcomes in Patients with Cardiomyopathy
inferred← citeshttps://doi.org/10.1007/s11897-021-00501-6openalex-snapshot
Reverse Cardiac Remodeling and ARNI Therapy
inferred← citeshttps://doi.org/10.1007/s11897-021-00529-8openalex-snapshot
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
inferred← citeshttps://doi.org/10.1007/s11897-024-00679-5openalex-snapshot
Clinical Update in Heart Failure with Preserved Ejection Fraction
inferred← citeshttps://doi.org/10.1007/s11906-024-01314-3openalex-snapshot
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
inferred← citeshttps://doi.org/10.1007/s12181-022-00555-3openalex-snapshot
Gemeinsamer Kommentar der Deutschen Gesellschaft für Kardiologie (DGK) und der Deutschen Gesellschaft für Thorax‑, Herz- und Gefäßchirurgie (DGTHG) zu den Leitlinien (2021) der ESC/EACTS zum Management von Herzklappenerkrankungen
inferred← citeshttps://doi.org/10.1007/s12181-022-00574-0openalex-snapshot
Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz (Teil 2)
inferred← citeshttps://doi.org/10.1007/s12265-022-10220-5openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
inferred← citeshttps://doi.org/10.1007/s12265-022-10302-4openalex-snapshot
Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism
inferred← citeshttps://doi.org/10.1007/s40005-026-00822-5openalex-snapshot
Cocrystal-enabled bilayer fixed-dose combination of empagliflozin and metformin: from solid-state design to clinical bioequivalence
inferred← citeshttps://doi.org/10.1007/s40200-024-01393-8openalex-snapshot
Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial
inferred← citeshttps://doi.org/10.1007/s40261-022-01166-2openalex-snapshot
Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1007/s40265-022-01778-0openalex-snapshot
Empagliflozin: A Review in Symptomatic Chronic Heart Failure
inferred← citeshttps://doi.org/10.1016/b978-0-443-15512-3.00005-2openalex-snapshot
Clinical Implications of Ventricular-Arterial Coupling and the Role of Therapeutic Interventions
inferred← citeshttps://doi.org/10.1016/j.ahj.2022.04.008openalex-snapshot
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial
inferred← citeshttps://doi.org/10.1016/j.ahj.2024.02.005openalex-snapshot
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program
inferred← citeshttps://doi.org/10.1016/j.ahj.2025.02.007openalex-snapshot
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial
inferred← citeshttps://doi.org/10.1016/j.ahj.2026.107398openalex-snapshot
Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial
inferred← citeshttps://doi.org/10.1016/j.ahj.2026.107541openalex-snapshot
Empagliflozin and functional capacity in patients at risk of heart failure
inferred← citeshttps://doi.org/10.1016/j.ahjo.2023.100264openalex-snapshot
Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial
inferred← citeshttps://doi.org/10.1016/j.amjcard.2021.03.001openalex-snapshot
Meta-Analysis of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients Without Diabetes
inferred← citeshttps://doi.org/10.1016/j.amjcard.2021.11.013openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization
inferred← citeshttps://doi.org/10.1016/j.amjcard.2022.05.023openalex-snapshot
Meta-analysis Analyzing the Effect of Therapies on 6-Minute Walk Distance in Heart Failure With Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1016/j.amjcard.2022.10.027openalex-snapshot
Meta-Analysis on the Safety and Efficacy of Sodium Glucose Cotransporters 2 Inhibitors in Patients With Heart Failure With and Without Diabetes
inferred← citeshttps://doi.org/10.1016/j.amjcard.2023.12.018openalex-snapshot
SGLT2 inhibitors in Patients Admitted for Acute Heart Failure: The Earlier the Better
inferred← citeshttps://doi.org/10.1016/j.amjcard.2026.05.012openalex-snapshot
Outcomes of Early Sodium-Glucose Cotransporter Two Inhibitor Use in Takotsubo Syndrome: Insights From a Multicenter Real-World Cohort Study
inferred← citeshttps://doi.org/10.1016/j.amjmed.2023.04.012openalex-snapshot
Chapter 4: Summary and a Patient Perspective on Living with Heart Failure
inferred← citeshttps://doi.org/10.1016/j.amjmed.2023.04.032openalex-snapshot
Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure
inferred← citeshttps://doi.org/10.1016/j.amjmed.2023.04.035openalex-snapshot
Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction
inferred← citeshttps://doi.org/10.1016/j.artere.2021.11.002openalex-snapshot
Role of newer antidiabetic drugs on cardiovascular prevention and heart failure
inferred← citeshttps://doi.org/10.1016/j.arteri.2021.02.013openalex-snapshot
Rol de nuevos fármacos antidiabéticos en prevención cardiovascular e insuficiencia cardiaca
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2023.117304openalex-snapshot
RAGE/DIAPH1 and atherosclerosis through an evolving lens: Viewing the cell from the “Inside – Out”
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2023.117306openalex-snapshot
Relationship between stress hyperglycemia and worsening heart failure in patients with significant secondary mitral regurgitation
inferred← citeshttps://doi.org/10.1016/j.biopha.2022.113606openalex-snapshot
Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115963openalex-snapshot
Empagliflozin alleviates the development of autoimmune myocarditis via inhibiting NF-κB-dependent cardiomyocyte pyroptosis
inferred← citeshttps://doi.org/10.1016/j.biopha.2024.116477openalex-snapshot
Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition
inferred← citeshttps://doi.org/10.1016/j.biopha.2024.116650openalex-snapshot
Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review
inferred← citeshttps://doi.org/10.1016/j.biopha.2025.118497openalex-snapshot
Empagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5/6 nephrectomy
inferred← citeshttps://doi.org/10.1016/j.cardfail.2021.07.003openalex-snapshot
The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure
inferred← citeshttps://doi.org/10.1016/j.cardfail.2021.08.014openalex-snapshot
De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry
inferred← citeshttps://doi.org/10.1016/j.cardfail.2024.12.001openalex-snapshot
Reassessing the need for primary prevention implantable cardioverter-defibrillators in contemporary patients with heart failure
inferred← citeshttps://doi.org/10.1016/j.cardfail.2026.01.025openalex-snapshot
The Effect of Empagliflozin on Left Ventricular Mass and Volumes in Older Adult Individuals With Overweight and High Risk of Heart Failure: The Empire Prevent Cardiac Trial
inferred← citeshttps://doi.org/10.1016/j.ccl.2021.04.007openalex-snapshot
New Antidiabetes Medications and Their Cardiovascular and Renal Benefits
inferred← citeshttps://doi.org/10.1016/j.cjco.2026.06.022openalex-snapshot
Prognostic Impact of a Simple GDMT Score on Clinical Outcomes and Cardiac Reverse Remodelling in Patients with ADHF: Insights from the JROADHF-Next Registry
inferred← citeshttps://doi.org/10.1016/j.cpcardiol.2023.101817openalex-snapshot
A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors
inferred← citeshttps://doi.org/10.1016/j.cpcardiol.2025.103231openalex-snapshot
Emerging risk factors for stroke and bleeding in patients with atrial fibrillation and heart failure–a narrative review
inferred← citeshttps://doi.org/10.1016/j.diabres.2022.109871openalex-snapshot
Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis
inferred← citeshttps://doi.org/10.1016/j.diabres.2022.110141openalex-snapshot
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)
inferred← citeshttps://doi.org/10.1016/j.diabres.2024.111796openalex-snapshot
Impact of age on eGFR dynamics following sodium-glucose cotransporter 2 inhibitor therapy: A real-world study
inferred← citeshttps://doi.org/10.1016/j.drudis.2025.104547openalex-snapshot
Therapeutic strategies for reversing cardiac fibrosis in hearts supported by ventricular assist devices
inferred← citeshttps://doi.org/10.1016/j.dsx.2021.102282openalex-snapshot
Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?
inferred← citeshttps://doi.org/10.1016/j.dsx.2022.102417openalex-snapshot
Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial
inferred← citeshttps://doi.org/10.1016/j.dsx.2026.103452openalex-snapshot
Comparative effects of SGLT2 inhibitors on Erythropoiesis: A systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.echo.2024.10.009openalex-snapshot
Dapagliflozin Effects on Left Ventricular Remodeling and Filling Pressures in Heart Failure With Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1016/j.echo.2025.01.002openalex-snapshot
Dapagliflozin and Cardiac Reverse Remodeling: New Insights in the Mechanistic Puzzle of SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1016/j.eclinm.2021.100933openalex-snapshot
SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ejim.2023.04.002openalex-snapshot
The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1016/j.ejphar.2021.174378openalex-snapshot
Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
inferred← citeshttps://doi.org/10.1016/j.ejphar.2023.175626openalex-snapshot
Analysis of the cardiac effects of sodium-glucose co-transporter 2 inhibitors in animals without diabetes and a clinical perspective
inferred← citeshttps://doi.org/10.1016/j.ejphar.2023.175729openalex-snapshot
SGLT2 inhibitor dapagliflozin alleviates intramyocardial hemorrhage and adverse ventricular remodeling via suppressing hepcidin in myocardial ischemia-reperfusion injury
inferred← citeshttps://doi.org/10.1016/j.ejphar.2023.176087openalex-snapshot
The impact of sodium-glucose Cotransporter-2 inhibitors on lipid profile: A meta-analysis of 28 randomized controlled trials
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2021.05.013openalex-snapshot
Redox signaling in heart failure and therapeutic implications
inferred← citeshttps://doi.org/10.1016/j.gendis.2023.101174openalex-snapshot
New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family
inferred← citeshttps://doi.org/10.1016/j.healun.2025.06.003openalex-snapshot
The International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014)
inferred← citeshttps://doi.org/10.1016/j.healun.2025.06.004openalex-snapshot
Authors Insights on the Updated International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014)
inferred← citeshttps://doi.org/10.1016/j.hfc.2022.03.003openalex-snapshot
SGLT2 Inhibitors in Heart Failure
inferred← citeshttps://doi.org/10.1016/j.hjc.2021.03.003openalex-snapshot
SGLT2 inhibitors – A new silver bullet
inferred← citeshttps://doi.org/10.1016/j.hjc.2023.05.007openalex-snapshot
Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial
inferred← citeshttps://doi.org/10.1016/j.hjc.2023.09.015openalex-snapshot
Men are from mars, but women are not from venus: The benefits of SGLT2 inhibitors after myocardial infarction are independent of gender
inferred← citeshttps://doi.org/10.1016/j.hlc.2026.03.065openalex-snapshot
Cardiogeriatric Predictors of Early Adverse Outcomes After Heart Failure Hospitalisation in Older Adults: Insights from a Real-World Cohort Study (Elder-SAT)
inferred← citeshttps://doi.org/10.1016/j.hrthm.2024.10.023openalex-snapshot
Subepicardial adipose tissue as a modulator of arrhythmias
inferred← citeshttps://doi.org/10.1016/j.hrthm.2024.10.078openalex-snapshot
Reassessing the need for primary prevention implantable cardioverter-defibrillators in contemporary patients with heart failure
inferred← citeshttps://doi.org/10.1016/j.ijcard.2021.10.008openalex-snapshot
Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ijcard.2023.131391openalex-snapshot
Impact of sacubitril/valsartan and gliflozins on cardiac resynchronization therapy response in ischemic and non-ischemic heart failure patients
inferred← citeshttps://doi.org/10.1016/j.ijcard.2025.133567openalex-snapshot
The complementary effects of GLP-1 receptor agonists and SGLT2 inhibitors in transthyretin cardiac amyloidosis patients: A retrospective multicenter cohort study
inferred← citeshttps://doi.org/10.1016/j.ijcha.2024.101539openalex-snapshot
Representation of women and racial minorities in SGLT2 inhibitors and heart failure clinical trials
inferred← citeshttps://doi.org/10.1016/j.intimp.2023.110072openalex-snapshot
New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling
inferred← citeshttps://doi.org/10.1016/j.jacadv.2025.101615openalex-snapshot
Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias
inferred← citeshttps://doi.org/10.1016/j.jacc.2020.11.029openalex-snapshot
The Pleiotropic Effects of SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1016/j.jacc.2021.02.005openalex-snapshot
SGLT-2 Inhibitors in Heart Failure
inferred← citeshttps://doi.org/10.1016/j.jacc.2021.07.045openalex-snapshot
NT-proBNP Response to Heart Failure Therapies
inferred← citeshttps://doi.org/10.1016/j.jacc.2021.07.046openalex-snapshot
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
inferred← citeshttps://doi.org/10.1016/j.jacc.2022.03.353openalex-snapshot
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction
inferred← citeshttps://doi.org/10.1016/j.jacc.2023.12.024openalex-snapshot
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1016/j.jacc.2024.03.405openalex-snapshot
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
inferred← citeshttps://doi.org/10.1016/j.jacc.2025.03.544openalex-snapshot
Heart Failure With Improved Ejection Fraction
inferred← citeshttps://doi.org/10.1016/j.jacc.2025.08.054openalex-snapshot
Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1016/j.jaccao.2024.01.007openalex-snapshot
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1016/j.jchf.2021.03.003openalex-snapshot
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/j.jchf.2021.04.014openalex-snapshot
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF
inferred← citeshttps://doi.org/10.1016/j.jchf.2021.05.006openalex-snapshot
Empagliflozin-Induced Changes in Epicardial Fat
inferred← citeshttps://doi.org/10.1016/j.jchf.2022.09.009openalex-snapshot
Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan
inferred← citeshttps://doi.org/10.1016/j.jchf.2023.07.010openalex-snapshot
Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status
inferred← citeshttps://doi.org/10.1016/j.jchf.2023.07.016openalex-snapshot
Mitral Interventions in Heart Failure
inferred← citeshttps://doi.org/10.1016/j.jchf.2024.08.017openalex-snapshot
Efficacy, Safety and Mechanistic Impact of a Heart Failure Guideline-Directed Medical Therapy Clinic
inferred← citeshttps://doi.org/10.1016/j.jcin.2024.12.025openalex-snapshot
SGLT2 Inhibition in Aortic Stenosis
inferred← citeshttps://doi.org/10.1016/j.jcte.2024.100335openalex-snapshot
SGLT2 inhibitors: Beyond glycemic control
inferred← citeshttps://doi.org/10.1016/j.jdiacomp.2023.108509openalex-snapshot
Echocardiographic evaluation of the effect of dapagliflozin on epicardial adipose tissue and left ventricular systolic function in type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1016/j.jhlto.2025.100331openalex-snapshot
Pediatric heart failure: Current approach and treatment
inferred← citeshttps://doi.org/10.1016/j.jpet.2026.104945openalex-snapshot
Reframing SGLT2 inhibition: Anti-inflammatory mechanisms and drug target insights emerging from EMPA-TROPISM
inferred← citeshttps://doi.org/10.1016/j.lanwpc.2023.100692openalex-snapshot
Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study
inferred← citeshttps://doi.org/10.1016/j.mri.2021.11.004openalex-snapshot
Not only how much, but also how to, when measuring epicardial adipose tissue
inferred← citeshttps://doi.org/10.1016/j.nexres.2025.101033openalex-snapshot
Impact of SGLT2 inhibition with Dapagliflozin on biomarkers and cardiac remodelling in chronic myocardial injury: A double-blind, randomized controlled trial
inferred← citeshttps://doi.org/10.1016/j.phrs.2022.106243openalex-snapshot
The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.phrs.2022.106524openalex-snapshot
Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation
inferred← citeshttps://doi.org/10.1016/j.phrs.2025.108032openalex-snapshot
Glycometabolic cardiac dysfunction in HFpEF: Lessons from multi-omics studies
inferred← citeshttps://doi.org/10.1016/j.rec.2022.04.019openalex-snapshot
SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?
inferred← citeshttps://doi.org/10.1016/j.rec.2024.01.011openalex-snapshot
Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts
inferred← citeshttps://doi.org/10.1016/j.recesp.2022.04.008openalex-snapshot
Los iSGLT2 en la insuficiencia cardiaca. ¿Sus beneficios pueden extenderse a todo el espectro de la fracción de eyección?
inferred← citeshttps://doi.org/10.1016/j.recesp.2024.01.005openalex-snapshot
Inhibición dual del SGLT1 y SGLT2: algo más que su suma
inferred← citeshttps://doi.org/10.1016/j.tem.2021.07.006openalex-snapshot
Ketone bodies for the failing heart: fuels that can fix the engine?
inferred← citeshttps://doi.org/10.1016/j.yjmcc.2022.03.005openalex-snapshot
Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects
inferred← citeshttps://doi.org/10.1016/s2213-8587(21)00292-8openalex-snapshot
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
inferred← citeshttps://doi.org/10.1021/acsptsci.4c00240openalex-snapshot
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Guardians against Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Heart Diseases
inferred← citeshttps://doi.org/10.1024/1661-8157/a003876openalex-snapshot
Therapie der Herzinsuffizienz mit reduzierter Auswurffraktion: Was ist neu in den Leitlinien 2021?
inferred← citeshttps://doi.org/10.1038/s41569-024-00997-0openalex-snapshot
Contemporary pharmacological treatment and management of heart failure
inferred← citeshttps://doi.org/10.1038/s41591-026-04408-4openalex-snapshot
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
inferred← citeshttps://doi.org/10.1038/s44161-023-00352-5openalex-snapshot
Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure
inferred← citeshttps://doi.org/10.1038/s44324-026-00119-zopenalex-snapshot
Dual SGLT1/2 inhibition with sotagliflozin improves cardiac function and metabolism in type 2 diabetic mice
inferred← citeshttps://doi.org/10.1038/s44325-025-00093-3openalex-snapshot
A contemporary review on heart failure with improved ejection fraction
inferred← citeshttps://doi.org/10.1053/j.ackd.2021.02.006openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes
inferred← citeshttps://doi.org/10.1080/00015385.2025.2538399openalex-snapshot
Metformin ameliorates blunted cardioprotective response of ischemic postconditioning in rats subjected to high fat diet
inferred← citeshttps://doi.org/10.1080/10408363.2021.1993439openalex-snapshot
Cardiovascular benefit of SGLT2 inhibitors
inferred← citeshttps://doi.org/10.1080/13543784.2023.2263354openalex-snapshot
SGLT2 inhibitors: an evidence-based update on cardiovascular implications
inferred← citeshttps://doi.org/10.1080/14656566.2021.1939675openalex-snapshot
An evaluation of canagliflozin for the treatment of type 2 diabetes: an update
inferred← citeshttps://doi.org/10.1080/14656566.2022.2143263openalex-snapshot
Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1080/14779072.2025.2534712openalex-snapshot
Impact of SGLT2 inhibitors on functional outcomes in heart failure patients according to the aetiology
inferred← citeshttps://doi.org/10.1080/14796678.2024.2360818openalex-snapshot
Empagliflozin in the treatment of heart failure
inferred← citeshttps://doi.org/10.1080/14796678.2025.2503666openalex-snapshot
SGLT2 inhibitors across the acute cardiac care spectrum: insights and perspectives
inferred← citeshttps://doi.org/10.1080/17425255.2022.2105693openalex-snapshot
Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties
showing the first 200 of 525 · page through all 525
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.